文献速递细菌感染、耐药与抗菌药物

儿童发热性尿路感染个体化与标准10日抗生素治疗疗效与安全性

Efficacy and safety of individualised versus standard 10-day antibiotic treatment in children with febrile urinary tract infection (INDI-UTI): a pragmatic, open-label, multicentre, randomised, controlled, non-inferiority trial in Denmark.
PubMed 文献 · Lancet Infect Dis · 2025-04-02

INDI-UTI试验在丹麦8家医院纳入408例3月龄至12岁发热性尿路感染患儿,随机接受个体化治疗或标准10日治疗。个体化组28天内复发性尿路感染差异为5.3个百分点(单侧97.5%CI -∞至11.1,非劣效性P=0.24),未达非劣效;但抗生素总天数中位数减少4.0天,抗生素相关不良事件发生率更低。

要点

  • 个体化组28天内复发性尿路感染23/205(11%),标准10日组12/203(6%),差异5.3个百分点,非劣效性未成立。
  • 个体化组抗生素总天数中位数6.0天,标准10日组10.0天,中位差-4.0天(97.5%CI -4.5至-3.7)。
  • 抗生素相关不良事件发生率个体化组6.8/100患者日,标准10日组11.1/100患者日,率比0.61。

核心结论

  • 个体化治疗组复发性尿路感染风险增加5.3个百分点,但减少了抗生素使用和不良事件天数。
  • 作者认为个体化治疗策略在多数发热性尿路感染患儿中具有减少抗生素暴露和相关损害的潜力,支持抗菌药物管理目标。
  • 作者指出需进一步研究识别需要10日治疗的患者,以避免影响对短疗程反应良好的多数患儿的照护。

研究设计与样本

  • INDI-UTI为实用性、开放标签、多中心、随机对照非劣效性试验,在丹麦8家医院开展。
  • 纳入3月龄至12岁、发热≥38°C、治疗开始24小时内、尿路致病菌显著生长的患儿,随机1:1分配至个体化组或标准10日组。
  • 个体化组在充分临床改善(即无发热、胁腹痛和排尿困难)后3天停药,最短疗程4天。
  • 主要结局为停药后28天内复发性尿路感染(非劣效界值7.5个百分点)和治疗开始28天内抗生素总天数(优效性评估)。
  • 意向性治疗人群为主要分析人群,安全性在所有纳入患者中评估;试验注册号NCT05301023。

主要发现

  • 2022年3月28日至2024年3月3日,694例患者评估资格,408例随机分配:个体化组205例(中位抗生素疗程5.3天,IQR 4.8至6.5),标准10日组203例(10.0天,IQR 10.0至10.0)。
  • 中位年龄1.5岁(IQR 0.7至5.4),女性326例(80%),男性82例(20%)。
  • 28天内复发性尿路感染:个体化组23/205(11%),标准10日组12/203(6%),差异5.3个百分点(单侧97.5%CI -∞至11.1,非劣效性P=0.24)。
  • 28天内抗生素总天数:个体化组中位数6.0天(IQR 5.3至7.5),标准10日组10.0天(IQR 10.0至10.0),中位差-4.0天(97.5%CI -4.5至-3.7,P<0.0001)。
  • 28天内抗生素相关不良事件发生率:个体化组6.8/100患者日,标准10日组11.1/100患者日,率比0.61(95%CI 0.47至0.80,P=0.0003);严重不良事件个体化组17/205(8%),标准10日组15/203(7%),差异0.9个百分点(95%CI -4.6至6.5,P=0.79)。

关键数值与推荐

  • 非劣效界值为7.5个百分点(复发性尿路感染率差异)。
  • 个体化组停药标准:充分临床改善即无发热、胁腹痛和排尿困难后3天,最短疗程4天。
  • 主要结局非劣效性检验:差异5.3个百分点,单侧97.5%CI -∞至11.1,P=0.24,未达非劣效。
  • 抗生素总天数优效性检验:中位差-4.0天(97.5%CI -4.5至-3.7),P<0.0001。
  • 抗生素相关不良事件率比0.61(95%CI 0.47至0.80),P=0.0003。

临床怎么用

  • 原文指出个体化治疗策略在多数发热性尿路感染患儿中具有减少抗生素暴露和相关损害的潜力,支持抗菌药物管理目标。
  • 作者指出需进一步研究识别需要10日治疗的患者,以避免影响对短疗程反应良好的多数患儿的照护。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal antibiotic duration for febrile urinary tract infection (UTI) in children remains uncertain. We aimed to assess whether individualised treatment was non-inferior to standard 10-day treatment in terms of recurrent UTI and superior in reducing overall antibiotic exposure. METHODS: INDI-UTI was a pragmatic, open-label, multicentre, randomised, controlled, non-inferiority trial conducted at eight Danish hospitals. Children aged 3 months to 12 years who were febrile (≥38°C), within 24 h of treatment start, and with significant growth of uropathogenic bacteria were randomly assigned (1:1) using a web-based module with randomly permuted blocks to individualised or standard 10-day treatment. Main exclusion criteria included known urinary tract abnormalities, complicated medical history, bacteraemia, and elevated serum creatinine. The individualised group stopped treatment 3 days after adequate clinical improvement (ie, absence of fever, flank pain, and dysuria), with a minimum treatment duration of 4 days. The primary outcomes were recurrent UTI within 28 days after treatment cessation (non-inferiority margin 7·5 percentage points) and total antibiotic days within 28 days of treatment initiation (superiority assessment). No sample size calculation was performed for the assessment of total antibiotic days. Safety was assessed in all included patients. Main analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT05301023. FINDINGS: Between March 28, 2022, and March 3, 2024, 694 patients were assessed for eligibility and 408 patients were randomly assigned to individualised (n=205; median antibiotic duration 5·3 days [IQR 4·8 to 6·5]) or standard 10-day treatment (n=203; 10·0 days [10·0 to 10·0]). Median age was 1·5 years (IQR 0·7 to 5·4), and there were 326 (80%) female and 82 (20%) male participants. Recurrent UTI within 28 days occurred in 23 (11%) of 205 patients in the individualised group and 12 (6%) of 203 patients in the standard 10-day group (difference 5·3 percentage points, one-sided 97·5% CI -∞ to 11·1, pnon_inferiority=0·24). Total antibiotic days within 28 days were 6·0 (IQR 5·3 to 7·5) in the individualised group and 10·0 (10·0 to 10·0) in the standard 10-day group (median difference -4·0 days [97·5% CI -4·5 to -3·7], p<0·0001). The incidence rate of antibiotic-related adverse events within 28 days was 6·8 per 100 patient-days in the individualised group and 11·1 per 100 patient-days in the standard 10-day group (rate ratio 0·61 [95% CI 0·47 to 0·80], p=0·0003). Serious adverse events occurred in 17 (8%) of 205 patients in the individualised group and 15 (7%) of 203 patients in the standard 10-day group (difference 0·9 percentage points [95% CI -4·6 to 6·5], p=0·79). INTERPRETATION: Children with febrile UTI assigned to individualised treatment duration had an increased risk of recurrent UTI (by 5·3 percentage points) but reduced antibiotic use and fewer adverse event days within 28 days compared with those assigned to standard 10-day treatment. These findings highlight the potential of individualised treatment strategies to reduce antibiotic exposure and associated harms in most children with febrile UTI, supporting antimicrobial stewardship goals. Further research is needed to identify those requiring 10-day treatment to avoid compromising care for most children with febrile UTI who respond well to shorter durations. FUNDING: Copenhagen University Hospital Rigshospitalet Research Fund, Innovation Fund Denmark, and Greater Copenhagen Health Science Partners.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Sethi NJ, Carlsen ELM, Tabassum A, et al. Efficacy and safety of individualised versus standard 10-day antibiotic treatment in children with febrile urinary tract infection (INDI-UTI): a pragmatic, open-label, multicentre, randomised, controlled, non-inferiority trial in Denmark. Lancet Infect Dis. 2025. PMID: 40187361. doi:10.1016/S1473-3099(25)00075-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。